(SNY) Sanofi - Ratings and Ratios
Vaccines, Immunology, Oncology, Neurology, Rare Diseases
EPS (Earnings per Share)
Revenue
Dividends
| Dividend Yield | 4.56% |
| Yield on Cost 5y | 5.63% |
| Yield CAGR 5y | 3.83% |
| Payout Consistency | 89.8% |
| Payout Ratio | 51.5% |
| Risk via 5d forecast | |
|---|---|
| Volatility | 23.5% |
| Value at Risk 5%th | 36.3% |
| Relative Tail Risk | -6.03% |
| Reward TTM | |
|---|---|
| Sharpe Ratio | 0.16 |
| Alpha | -3.82 |
| CAGR/Max DD | 0.20 |
| Character TTM | |
|---|---|
| Hurst Exponent | 0.345 |
| Beta | 0.319 |
| Beta Downside | 0.182 |
| Drawdowns 3y | |
|---|---|
| Max DD | 21.87% |
| Mean DD | 8.90% |
| Median DD | 8.58% |
Description: SNY Sanofi December 02, 2025
Sanofi (NASDAQ:SNY) is a global integrated healthcare company that discovers, develops, manufactures, and markets a broad portfolio of therapeutic solutions, spanning immunology, rare diseases, neurology, oncology, and vaccines-including pediatric, respiratory syncytial virus, hexavalent, influenza, meningitis, and travel-endemic vaccines.
The firm leverages an extensive partnership network to augment its pipeline: collaborations with Exscientia (up to 15 novel small-molecule candidates), ABL Bio (alpha-synucleinopathy therapy), Innate Pharma (NK-cell engager), Blackstone Life Sciences (clinical development), IGM Biosciences (IgM antibodies), Kymera and Nurix (protein degraders), Denali (systemic inflammatory diseases), Adagene (antibody discovery), Scribe Therapeutics (genome editing), and a co-promotion deal with Provention Bio for teplizumab, plus a strategic alliance with Abu Dhabi’s Department of Health for global vaccine development.
Key recent metrics: 2023 total revenue of ≈ $44.5 billion, with vaccine sales up ~7% YoY driven by COVID-19 booster demand; R&D spend of ≈ $7.2 billion (≈16% of revenue), reflecting heavy investment in biologics and protein-degradation platforms; and a dividend yield around 3.6%, positioning Sanofi as a relatively high-yielding player in the mature pharma sector.
Sector drivers that materially affect Sanofi include aging demographics boosting demand for chronic-disease therapeutics, persistent vaccine-related public-health spending, and the industry-wide shift toward advanced modalities (e.g., mRNA, protein degraders) that require sizable partnership ecosystems.
For a deeper, data-driven valuation of Sanofi, explore the analyst toolkit on ValueRay.
Piotroski VR‑10 (Strict, 0-10) 4.5
| Net Income (9.11b TTM) > 0 and > 6% of Revenue (6% = 2.53b TTM) |
| FCFTA 0.06 (>2.0%) and ΔFCFTA -2.14pp (YES ≥ +1.0pp, WARN ≥ +0.5pp) |
| NWC/Revenue 4.60% (prev -36.66%; Δ 41.25pp) (YES ≤20% & Δ≤-1pp; WARN ≤25% & Δ≤0 oder ≤40% & Δ≤-3pp) |
| CFO/TA 0.06 (>3.0%) and CFO 7.30b <= Net Income 9.11b (YES >=105%, WARN >=100%) |
| Net Debt (12.85b) to EBITDA (9.44b) ratio: 1.36 <= 3.0 (WARN <= 3.5) |
| Current Ratio 1.06 (target 1.5–3.0; WARN 1.2–<1.5 or >3.0–5.0; CFO/TA gate active) |
| Outstanding Shares last Quarter (2.47b) change vs 12m ago -1.52% (target <= -2.0% for YES) |
| Gross Margin 72.56% (prev 69.43%; Δ 3.13pp) >=18% & Δ>=+0.5pp (WARN >=15% & Δ>=0) |
| Asset Turnover 32.89% (prev 37.53%; Δ -4.64pp) >=50% & Δ>=+2pp (WARN >=35% & Δ>=0) |
| Interest Coverage Ratio 8.45 (EBITDA TTM 9.44b / Interest Expense TTM 943.5m) >= 6 (WARN >= 3) |
ValueRay F-Score (Strict, 0-100) 63.65
| 1. Piotroski 4.50pt |
| 2. FCF Yield 6.51% |
| 3. FCF Margin 17.33% |
| 4. Debt/Equity 0.30 |
| 5. Debt/Ebitda 1.36 |
| 6. ROIC - WACC (= 0.89)% |
| 7. RoE 12.36% |
| 8. Rev. Trend 3.05% |
| 9. EPS Trend 10.60% |
What is the price of SNY shares?
Over the past week, the price has changed by +0.60%, over one month by -3.12%, over three months by +6.43% and over the past year by +4.52%.
Is SNY a buy, sell or hold?
- Strong Buy: 5
- Buy: 3
- Hold: 3
- Sell: 0
- Strong Sell: 0
What are the forecasts/targets for the SNY price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 59.4 | 22.4% |
| Analysts Target Price | 59.4 | 22.4% |
| ValueRay Target Price | 51.8 | 6.9% |
SNY Fundamental Data Overview December 24, 2025
P/E Trailing = 15.645
P/E Forward = 9.6993
P/S = 2.5525
P/B = 1.3603
P/EG = 0.7239
Beta = 0.371
Revenue TTM = 42.14b EUR
EBIT TTM = 7.97b EUR
EBITDA TTM = 9.44b EUR
Long Term Debt = 11.70b EUR (from longTermDebt, last quarter)
Short Term Debt = 8.49b EUR (from shortTermDebt, last quarter)
Debt = 21.75b EUR (from shortLongTermDebtTotal, last quarter)
Net Debt = 12.85b EUR (from netDebt column, last quarter)
Enterprise Value = 112.28b EUR (99.43b + Debt 21.75b - CCE 8.91b)
Interest Coverage Ratio = 8.45 (Ebit TTM 7.97b / Interest Expense TTM 943.5m)
FCF Yield = 6.51% (FCF TTM 7.30b / Enterprise Value 112.28b)
FCF Margin = 17.33% (FCF TTM 7.30b / Revenue TTM 42.14b)
Net Margin = 21.62% (Net Income TTM 9.11b / Revenue TTM 42.14b)
Gross Margin = 72.56% ((Revenue TTM 42.14b - Cost of Revenue TTM 11.56b) / Revenue TTM)
Gross Margin QoQ = 74.09% (prev 72.13%)
Tobins Q-Ratio = 0.87 (Enterprise Value 112.28b / Total Assets 129.79b)
Interest Expense / Debt = 1.04% (Interest Expense 227.0m / Debt 21.75b)
Taxrate = 19.38% (680.0m / 3.51b)
NOPAT = 6.43b (EBIT 7.97b * (1 - 19.38%))
Current Ratio = 1.06 (Total Current Assets 34.04b / Total Current Liabilities 32.10b)
Debt / Equity = 0.30 (Debt 21.75b / totalStockholderEquity, last quarter 73.26b)
Debt / EBITDA = 1.36 (Net Debt 12.85b / EBITDA 9.44b)
Debt / FCF = 1.76 (Net Debt 12.85b / FCF TTM 7.30b)
Total Stockholder Equity = 73.71b (last 4 quarters mean from totalStockholderEquity)
RoA = 7.02% (Net Income 9.11b / Total Assets 129.79b)
RoE = 12.36% (Net Income TTM 9.11b / Total Stockholder Equity 73.71b)
RoCE = 9.33% (EBIT 7.97b / Capital Employed (Equity 73.71b + L.T.Debt 11.70b))
RoIC = 6.94% (NOPAT 6.43b / Invested Capital 92.60b)
WACC = 6.05% (E(99.43b)/V(121.18b) * Re(7.19%) + D(21.75b)/V(121.18b) * Rd(1.04%) * (1-Tc(0.19)))
Discount Rate = 7.19% (= CAPM, Blume Beta Adj.) -> floored to rf + 0.7*ERP = 8.05%
Shares Correlation 3-Years: -81.65 | Cagr: -0.79%
[DCF Debug] Terminal Value 74.22% ; FCFE base≈8.31b ; Y1≈6.53b ; Y5≈4.27b
Fair Price DCF = 32.79 (DCF Value 79.65b / Shares Outstanding 2.43b; 5y FCF grow -25.63% → 3.0% )
EPS Correlation: 10.60 | EPS CAGR: 22.46% | SUE: 0.22 | # QB: 0
Revenue Correlation: 3.05 | Revenue CAGR: 6.46% | SUE: 0.30 | # QB: 0
EPS next Quarter (2026-03-31): EPS=0.99 | Chg30d=-0.015 | Revisions Net=-1 | Analysts=1
EPS next Year (2026-12-31): EPS=4.96 | Chg30d=-0.015 | Revisions Net=-2 | Growth EPS=+8.7% | Growth Revenue=+6.8%
Additional Sources for SNY Stock
Tweets: X | Stocktwits
Fund Manager Positions: Dataroma | Stockcircle